Tickers

1. Composite Trajectory Verdict

The income statement carries the most weight for assessing ALNY's trajectory because the company transitioned from cumulative losses to GAAP profitability in 2025, and its business model is now funded primarily by product revenues rather than external financing.

Composite Trajectory: Improving

Revenue grew 65% year-over-year to $3.714 billion in 2025, driven by an 81% increase in net product revenues to $2.987 billion (10-K 2025-12-31, Consolidated Statements of Operations). Operating income swung from a $177 million loss in 2024 to a $502 million gain in 2025, and net income turned positive at $314 million versus a $278 million loss (10-K 2025-12-31, Consolidated Statements of Operations). Operating cash flow improved from negative $8 million to positive $524 million (10-K 2025-12-31, Consolidated Statements of Cash Flows). Stockholders' equity rose from $67 million to $789 million, while cash and marketable securities increased to $2.91 billion from $2.69 billion (10-K 2025-12-31, Consolidated Balance Sheets; MD&A Liquidity and Capital Resources). These improvements outweigh the margin pressure from rising AMVUTTRA royalties and higher interest expense on development funding liabilities.

2. Red Flags

• Cost of goods sold as a percentage of net product revenues rose from 18.6% in 2024 to 22.7% in 2025 due to tiered royalties on AMVUTTRA sales to Sanofi, and the company expects this percentage to increase further in 2026 (10-K 2025-12-31, MD&A Cost of Goods Sold).
• Interest expense jumped 78% to $253 million in 2025 from $142 million in 2024, driven by the adoption of ASU 2025-07 (which reclassified development funding liabilities as debt with effective rates of 46% for vutrisiran and 32% for zilebesiran) and a $42 million inducement expense from repurchasing 2027 convertible notes (10-K 2025-12-31, MD&A Other (Expense) Income; Note 9).
• Liabilities related to the sale of future royalties and development funding grew to $1.69 billion at year-end 2025 from $1.45 billion at year-end 2024, with the Leqvio royalty liability alone at $1.48 billion carrying a 10% effective interest rate (10-K 2025-12-31, Consolidated Balance Sheets; Note 9).
• Accumulated deficit remains substantial at $6.70 billion despite the 2025 profit (10-K 2025-12-31, Consolidated Balance Sheets).
• A government subpoena received in October 2025 seeks documents on government price reporting for AMVUTTRA, ONPATTRO, OXLUMO and GIVLAARI (10-K 2025-12-31, Note 13 Government Investigation).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Total revenues increased 65% to $3.714 billion in 2025 from $2.248 billion in 2024, with net product revenues up 81% to $2.987 billion (10-K 2025-12-31, Consolidated Statements of Operations). AMVUTTRA revenues more than doubled to $2.314 billion from $970 million, while ONPATTRO declined 32% to $173 million (10-K 2025-12-31, MD&A Net Product Revenues). Operating income swung to a $502 million gain from a $177 million loss, and net income reached $314 million versus a $278 million loss (10-K 2025-12-31, Consolidated Statements of Operations). R&D expense rose 17% to $1.320 billion and SG&A rose 24% to $1.211 billion, but both grew slower than revenue (10-K 2025-12-31, MD&A Operating Costs and Expenses). Royalty revenue nearly doubled to $174 million from $92 million (10-K 2025-12-31, Consolidated Statements of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Net cash provided by operating activities surged to $524 million in 2025 from negative $8 million in 2024, driven by stronger cash receipts from product sales (10-K 2025-12-31, Consolidated Statements of Cash Flows; MD&A Operating Activities). Investing activities provided $436 million in 2025 versus using $117 million in 2024, primarily from net sales and maturities of marketable securities (10-K 2025-12-31, Consolidated Statements of Cash Flows; MD&A Investing Activities). Financing activities used $305 million in 2025 compared to providing $294 million in 2024, reflecting $1.15 billion of 2027 note repurchases partially offset by $646 million of 2028 note proceeds (10-K 2025-12-31, Consolidated Statements of Cash Flows; MD&A Financing Activities). Cash, cash equivalents and restricted cash ended 2025 at $1.659 billion, up from $969 million at end-2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Total assets grew to $4.97 billion at December 31, 2025 from $4.24 billion a year earlier (10-K 2025-12-31, Consolidated Balance Sheets). Cash and marketable securities increased to $2.91 billion from $2.69 billion (10-K 2025-12-31, Consolidated Balance Sheets; MD&A Liquidity and Capital Resources). Accounts receivable nearly doubled to $778 million from $405 million due to higher sales (10-K 2025-12-31, Consolidated Balance Sheets). Total liabilities were roughly flat at $4.18 billion versus $4.17 billion, though liabilities for future royalties and development funding rose to $1.69 billion from $1.45 billion (10-K 2025-12-31, Consolidated Balance Sheets). Stockholders' equity improved markedly to $789 million from $67 million, aided by 2025 net income of $314 million and a $271 million cumulative-effect adjustment from adopting ASU 2025-07 (10-K 2025-12-31, Consolidated Statements of Stockholders' Equity; Note 2).

6. Data Gaps

• Quarterly financial statements for 2026 (10-Qs for Q1, Q2, Q3 2026) were listed as provided but their detailed contents were truncated in the supplied materials, preventing quarter-over-quarter trend analysis.
• Non-GAAP metrics referenced in MD&A (e.g., non-GAAP R&D, non-GAAP operating margin) are not reconciled in the provided excerpts.
• Detailed breakdown of 2026 expected capital expenditures beyond "increase to support manufacturing capacity" (MD&A Additional Capital Requirements).
• Full terms of the Revolving Credit Agreement covenants and current leverage/interest coverage ratios (only compliance stated).
• Resolution timeline or potential financial impact of the October 2025 government subpoena (Note 13).